BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant
Shares of BioAffinity Technologies are surging Thursday after securing a key Hong Kong patent for its CyPath Lung diagnostic.
Share
Why It Matters
BioAffinity got a patent to use its lung test in Hong Kong. This means the company can now sell its product in that country.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.